https://www.pharmaradar360.com/article/drug-label-update-evereden-kids-mineral-sunscreen-spf-30-bd2e8f7ef3f473aaPharma Surgeen2026-07-01T00:00:00.000ZDrug label update: Evereden Kids Mineral Sunscreen SPF 30https://www.pharmaradar360.com/article/drug-label-update-guna-virus-3eb3bf9cba150338Pharma Surgeen2026-07-01T00:00:00.000ZDrug label update: GUNA-VIRUShttps://www.pharmaradar360.com/article/what-does-a-medieval-calf-look-like-in-mass-spectrometry-d1422e8d3ef2823bPharma Surgeen2026-06-30T11:26:30.000ZWhat does a medieval calf look like in mass spectrometry?https://www.pharmaradar360.com/article/mag-7-action-improves-but-biotech-keeps-delivering-the-real-wins-a902788400556c08Pharma Surgeen2026-06-30T11:21:00.000ZMag 7 Action Improves, But Biotech Keeps Delivering the Real Winshttps://www.pharmaradar360.com/article/criion-joachim-frank-prize-2026-awarded-to-cancer-researchers-in-freiburg-9cf1b40ba58793a8Pharma Surgeen2026-06-30T11:19:37.000ZCRIION Joachim Frank Prize 2026 awarded to cancer researchers in Freiburghttps://www.pharmaradar360.com/article/unicycive-s-kidney-drug-hits-fda-setback-as-label-talks-continue-f73eeb319f397fd2Pharma Surgeen2026-06-30T11:05:00.000ZUnicycive’s kidney drug hits FDA setback as label talks continuehttps://www.pharmaradar360.com/article/unicycive-therapeutics-receives-complete-response-letter-7588ba6eb03c7a80Pharma Surgeen2026-06-30T11:05:00.000ZUnicycive Therapeutics Receives Complete Response Letterhttps://www.pharmaradar360.com/article/hamptons-heart-ball-raises-funds-to-fight-heart-disease-and-stroke-1bda0ea251fad4c6Pharma Surgeen2026-06-30T11:00:00.000ZHamptons Heart Ball raises funds to fight heart disease and strokehttps://www.pharmaradar360.com/article/financialcontent-sizzling-stocks-under-5-upc-any-nnbr-dcoy-target-ai-infrastruct-0b678f7207fd87aaPharma Surgeen2026-06-30T10:29:00.000ZFinancialContent - Sizzling Stocks Under $5: UPC, ANY, NNBR, DCOY Target AI Infrastructure, Data Centers, Pharmaceutical Innovation and Biotechnology Growthhttps://www.pharmaradar360.com/article/rats-cockroaches-rotting-food-fda-suspends-six-mumbai-eateries-in-hygiene-crackd-690a46a44def32e4Pharma Surgeen2026-06-30T10:25:23.000ZRats, cockroaches, rotting food: FDA suspends six Mumbai eateries in hygiene crackdownhttps://www.pharmaradar360.com/article/information-about-the-criminal-offence-committed-by-a-former-employee-of-the-uni-afeb1817cf8f5ce8Pharma Surgeen2026-06-30T10:21:00.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/india-s-first-homegrown-antibiotic-zaynich-gets-us-fda-approval-here-s-what-you-a4a279c939252c55Pharma Surgeen2026-06-30T10:14:27.000ZIndia's First Homegrown Antibiotic Zaynich Gets US FDA Approval; Here's What You Need To Know About The Drughttps://www.pharmaradar360.com/article/university-elections-2026-c3b78142c55dc9d4Pharma Surgeen2026-06-30T10:09:16.000ZUniversity Elections 2026https://www.pharmaradar360.com/article/biotech-etf-bbc-touches-a-new-52-week-high-c6d3203477fa551bPharma Surgeen2026-06-30T10:06:51.000ZBiotech ETF (BBC) Touches a New 52-Week Highhttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-relonchem-limited-gabapentin-relonchem-50m-061aa46b22f7032ePharma Surgeen2026-06-30T10:06:09.000ZClass 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31https://www.pharmaradar360.com/article/obesity-drugs-after-the-gold-rush-ddb815cdc0f5b235Pharma Surgeen2026-06-30T10:03:58.000ZObesity drugs after the gold rushhttps://www.pharmaradar360.com/article/public-asked-to-nominate-their-local-nhs-heroes-for-nhsggc-people-s-choice-award-3fa1d7d1ae66731ePharma Surgeen2026-06-30T10:00:55.000ZPublic asked to nominate their local NHS heroes for NHSGGC People’s Choice Awardhttps://www.pharmaradar360.com/article/quadram-institute-announces-major-european-research-milestone-in-myalgic-encepha-d80c8db9eb62ae80Pharma Surgeen2026-06-30T09:48:17.000ZQuadram Institute Announces Major European Research Milestone in Myalgic Encephalomyelitis (ME)https://www.pharmaradar360.com/article/can-hansoh-pharmaceutical-monetize-its-expanding-drug-portfolio-79cc0770efd49919Pharma Surgeen2026-06-30T09:37:45.000ZCan Hansoh Pharmaceutical Monetize Its Expanding Drug Portfolio?https://www.pharmaradar360.com/article/mass-biotech-ipo-proceeds-near-3-2b-close-in-on-pandemic-era-record-pace-4e0ff3c307f8cedcPharma Surgeen2026-06-30T09:37:00.000ZMass. biotech IPO proceeds near $3.2B, close in on pandemic-era record pacehttps://www.pharmaradar360.com/article/salipro-biotech-announces-publication-in-nature-scientific-reports-on-expanding-179d6d88012b9ac4Pharma Surgeen2026-06-30T09:30:00.000ZSalipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteinshttps://www.pharmaradar360.com/article/a-new-injection-is-helping-people-with-copd-breathe-more-easily-df4f38795737c9eePharma Surgeen2026-06-30T09:24:50.000ZA new injection is helping people with COPD breathe more easilyhttps://www.pharmaradar360.com/article/den-ursachen-der-spina-bifida-auf-der-spur-da1088caa88f09f9Pharma Surgeen2026-06-30T09:14:16.000ZDen Ursachen der Spina bifida auf der Spurhttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-6616af9917829d3aPharma Surgeen2026-06-30T09:04:29.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/package-deals-in-the-pharmaceutical-industry-and-disclosure-uk-data-089383a666793338Pharma Surgeen2026-06-30T09:04:15.000ZPackage deals in the pharmaceutical industry and Disclosure UK datahttps://www.pharmaradar360.com/article/cells-boundaries-and-the-emergence-of-biological-order-6574a69fcb9fd82bPharma Surgeen2026-06-30T09:01:56.000ZCells, boundaries, and the emergence of biological orderhttps://www.pharmaradar360.com/article/kff-polling-on-health-information-and-trust-49822802bc264ee0Pharma Surgeen2026-06-30T09:00:13.000ZKFF Polling on Health Information and Trusthttps://www.pharmaradar360.com/article/kff-tracking-poll-on-health-information-and-trust-update-on-common-vaccine-myths-3560ca42cc15dfa7Pharma Surgeen2026-06-30T09:00:00.000ZKFF Tracking Poll on Health Information and Trust: Update on Common Vaccine Mythshttps://www.pharmaradar360.com/article/poll-people-without-a-trusted-health-care-provider-are-more-likely-to-endorse-va-dc02770fbec8b2e9Pharma Surgeen2026-06-30T09:00:00.000ZPoll: People Without a Trusted Health Care Provider Are More Likely to Endorse Vaccine Myths, As Are Those Who Often Use Social Media or AI for Health Informationhttps://www.pharmaradar360.com/article/everyone-is-the-main-character-in-their-own-story-at-maria-pepe-42badf493c5c3d11Pharma Surgeen2026-06-30T09:00:00.000ZEveryone is the main character in their own story at Maria & Pepehttps://www.pharmaradar360.com/article/next-generation-scans-now-helping-patients-at-royal-brompton-ae2bb99b8e1c48a9Pharma Surgeen2026-06-30T08:56:08.000ZNext-generation scans now helping patients at Royal Bromptonhttps://www.pharmaradar360.com/article/crg-signs-mou-with-shenzhen-institutes-smart-and-szbl-51525d4463d0197ePharma Surgeen2026-06-30T08:54:52.000ZCRG signs MoU with Shenzhen institutes SMART and SZBLhttps://www.pharmaradar360.com/article/lonza-usa-eyes-1-billion-clermont-county-biotech-plant-ohio-b5fa3a5c00ce46a8Pharma Surgeen2026-06-30T08:47:41.000ZLonza USA Eyes $1 Billion Clermont County Biotech Plant, Ohiohttps://www.pharmaradar360.com/article/ukhsa-evaluation-strategy-b5835dc077e447e2Pharma Surgeen2026-06-30T08:30:00.000ZUKHSA Evaluation Strategyhttps://www.pharmaradar360.com/article/russia-and-cuba-set-up-first-joint-pharmaceutical-venture-36ea979131b17e4ePharma Surgeen2026-06-30T08:18:22.000ZRussia and Cuba set up first joint pharmaceutical venturehttps://www.pharmaradar360.com/article/price-to-book-forward-of-proto-script-pharmaceutical-corp-otc-pscr-0a2585d8b9a61803Pharma Surgeen2026-06-30T08:03:27.000ZPrice to book forward of PROTO SCRIPT PHARMACEUTICAL CORP – OTC:PSCRhttps://www.pharmaradar360.com/article/pfas-in-medicines-can-often-be-replaced-with-alternatives-ffc499c6277bf675Pharma Surgeen2026-06-30T08:01:52.000ZPFAS in medicines can often be replaced with alternativeshttps://www.pharmaradar360.com/article/fda-a72cac3827eb8431Pharma Surgeen2026-06-30T08:00:00.000Zエンスプリングに関するロシュ社の発表について（甲状腺眼症に対する申請が米国FDAに受理）https://www.pharmaradar360.com/article/roche-s-announcement-regarding-enspryng-fda-accepts-application-for-thyroid-eye-a4caf8c0a146634fPharma Surgeen2026-06-30T08:00:00.000ZRoche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)https://www.pharmaradar360.com/article/wuxi-biologics-receives-brazil-anvisa-gmp-certification-to-enable-global-commerc-5676096b2de3dda1Pharma Surgeen2026-06-30T07:58:10.000ZWuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapyhttps://www.pharmaradar360.com/article/australians-voice-outlook-and-rising-impact-of-wicked-problems-c300d273181a016bPharma Surgeen2026-06-30T07:22:49.000ZAustralians voice outlook and rising impact of wicked problemshttps://www.pharmaradar360.com/article/scientists-may-have-finally-found-how-alzheimer-s-spreads-through-the-brain-6d1a241ed4b60426Pharma Surgeen2026-06-30T07:21:06.000ZScientists may have finally found how Alzheimer's spreads through the brainhttps://www.pharmaradar360.com/article/global-biopharmaceutical-ceos-response-to-reforms-introduced-in-germany-dd88dba49d4267f6Pharma Surgeen2026-06-30T07:20:42.000ZGlobal biopharmaceutical CEOs response to reforms introduced in Germanyhttps://www.pharmaradar360.com/article/weather-stations-measure-record-breaking-temperatures-in-freiburg-city-6ca2a853a369577dPharma Surgeen2026-06-30T07:16:17.000ZWeather stations measure record-breaking temperatures in Freiburg Cityhttps://www.pharmaradar360.com/article/french-biotech-stock-soars-34-after-new-data-on-experimental-medicine-2a6d2ca2fc700843Pharma Surgeen2026-06-30T07:13:05.000ZFrench biotech stock soars 34% after new data on experimental medicinehttps://www.pharmaradar360.com/article/from-wound-care-to-prevention-keeping-people-with-diabetes-on-their-feet-f3155102c2f313edPharma Surgeen2026-06-30T07:12:28.000ZFrom wound care to prevention: Keeping people with diabetes on their feethttps://www.pharmaradar360.com/article/adragos-signs-agreement-with-towa-pharmaceutical-to-supply-off-patent-medicines-b2c995bf1e31617dPharma Surgeen2026-06-30T07:10:35.000ZAdragos signs agreement with Towa Pharmaceutical to supply off-patent medicineshttps://www.pharmaradar360.com/article/joint-statement-on-warning-to-pharmacists-about-diverted-hiv-medicines-being-sol-40552ace77c6c496Pharma Surgeen2026-06-30T07:03:12.000ZJoint Statement on Warning to Pharmacists About Diverted HIV Medicines Being Sold on Online Pharmacy-to-Pharmacy Platformshttps://www.pharmaradar360.com/article/first-aid-biotech-battle-moves-to-parliament-2ddd4b81b60b6ad5Pharma Surgeen2026-06-30T07:00:31.000ZFIRST AID: Biotech battle moves to Parliamenthttps://www.pharmaradar360.com/article/regents-approve-interim-structure-for-nebraska-medicine-governance-ed298b81ec6880cdPharma Surgeen2026-06-30T07:00:00.000ZRegents approve interim structure for Nebraska Medicine governancehttps://www.pharmaradar360.com/article/rassegnastampa-il-cervello-non-va-in-vacanza-ma-il-caldo-lo-mette-a-dura-prova-m-5947a47f6bc6b7ddPharma Surgeen2026-06-30T07:00:00.000Z#RASSEGNASTAMPA. Il cervello non va in vacanza (ma il caldo lo mette a dura prova). Marco Locatelli a Radio 24https://www.pharmaradar360.com/article/teamwork-in-academia-through-teamwork-we-get-inspiration-and-innovation-going-6f2a02789fc1a098Pharma Surgeen2026-06-30T07:00:00.000ZTeamwork in academia: “through teamwork, we get inspiration and innovation going.”https://www.pharmaradar360.com/article/towards-an-eu-clinical-trials-competitiveness-initiative-restoring-europe-s-edge-e192bcdc7d5ef7d4Pharma Surgeen2026-06-30T06:58:21.000ZTowards an EU clinical trials competitiveness initiative: restoring Europe's edgehttps://www.pharmaradar360.com/article/unmc-team-studying-neuroinflammation-in-people-with-hiv-acc9678396e9d72dPharma Surgeen2026-06-30T06:58:00.000ZUNMC team studying neuroinflammation in people with HIVhttps://www.pharmaradar360.com/article/portions-of-mcgoogan-library-to-reopen-tuesday-d4b9fc7dd829cbd6Pharma Surgeen2026-06-30T06:56:00.000ZPortions of McGoogan Library to reopen Tuesdayhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-takeda-pharmaceutical-co-ltd-tse-4502-e63edabf81de1f8fPharma Surgeen2026-06-30T06:55:40.000ZEnterprise value to revenue forward of Takeda Pharmaceutical Co. Ltd. – TSE:4502https://www.pharmaradar360.com/article/med-center-shuttle-out-of-service-this-friday-6b65454b33aca243Pharma Surgeen2026-06-30T06:54:00.000ZMed center shuttle out of service this Fridayhttps://www.pharmaradar360.com/article/genmab-s-epcoritamab-plus-lenalidomide-meets-phase-3-goal-in-relapsed-dlbcl-41c406ee2951ced8Pharma Surgeen2026-06-30T06:53:10.000ZGenmab’s Epcoritamab Plus Lenalidomide Meets Phase 3 Goal in Relapsed DLBCLhttps://www.pharmaradar360.com/article/leeds-research-and-innovation-annual-conference-2026-8eb222d30fa96b56Pharma Surgeen2026-06-30T06:33:41.000ZLeeds Research and Innovation Annual Conference 2026https://www.pharmaradar360.com/article/number-of-shares-and-votes-in-active-biotech-eada6aa6eb651f00Pharma Surgeen2026-06-30T06:31:16.000ZNumber of shares and votes in Active Biotechhttps://www.pharmaradar360.com/article/ai-llm-62e238dcb1d9cb78Pharma Surgeen2026-06-30T06:30:00.000Z治験候補患者抽出の精度向上・効率化に向け、リアルワールドデータと生成AI（LLM）を用いた共同研究を開始https://www.pharmaradar360.com/article/launch-of-joint-research-using-real-world-data-and-generative-ai-llm-to-improve-b9ae34b323f26797Pharma Surgeen2026-06-30T06:30:00.000ZLaunch of Joint Research Using Real-World Data and Generative AI (LLM) to Improve the Accuracy and Efficiency of Identifying Candidate Patients for Clinical Trialshttps://www.pharmaradar360.com/article/number-of-shares-and-votes-in-active-biotech-da30b5412c865194Pharma Surgeen2026-06-30T06:30:00.000ZNumber of shares and votes in Active Biotechhttps://www.pharmaradar360.com/article/scientists-say-creatine-may-help-fight-depression-30cc8b49b58d1927Pharma Surgeen2026-06-30T06:28:57.000ZScientists say creatine may help fight depressionhttps://www.pharmaradar360.com/article/fran-forrad-till-livsviktig-resurs-nu-rustas-skyddsrummen-upp-58d3252c009ab317Pharma Surgeen2026-06-30T06:20:22.000ZFrån förråd till livsviktig resurs – nu rustas skyddsrummen upphttps://www.pharmaradar360.com/article/rethinking-clinical-outcome-assessments-what-sentiment-analysis-reveals-about-pa-fb6b91630e003acbPharma Surgeen2026-06-30T05:56:57.000ZRethinking Clinical Outcome Assessments: What Sentiment Analysis Reveals About Patient Feedbackhttps://www.pharmaradar360.com/article/rats-cockroaches-found-in-6-mumbai-restaurants-fda-suspends-licences-101645a4d3a04f0ePharma Surgeen2026-06-30T05:50:57.000ZRats, cockroaches found in 6 Mumbai restaurants, FDA suspends licenceshttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hatinh-pharmaceutical-joint-stock-co-upcom-39ee08754a962fe7Pharma Surgeen2026-06-30T05:35:15.000ZEnterprise value to EBITDA forward of HaTinh Pharmaceutical Joint Stock Co – UPCOM:HDPhttps://www.pharmaradar360.com/article/mumbai-food-dept-finds-rats-cockroaches-expired-food-at-six-eateries-located-in-795eb7cf008e9232Pharma Surgeen2026-06-30T05:34:00.000ZMumbai food dept finds rats, cockroaches, expired food at six eateries located in Nariman Point, Borivali,https://www.pharmaradar360.com/article/price-to-earnings-forward-of-hatinh-pharmaceutical-joint-stock-co-upcom-hdp-e2bf134b43190da2Pharma Surgeen2026-06-30T05:32:51.000ZPrice to earnings forward of HaTinh Pharmaceutical Joint Stock Co – UPCOM:HDPhttps://www.pharmaradar360.com/article/2027-step-out-walk-baltimore-e157ac86bc9d93fbPharma Surgeen2026-06-30T05:31:21.000Z2027 Step Out® Walk: Baltimorehttps://www.pharmaradar360.com/article/price-to-book-forward-of-zhejiang-wolwo-bio-pharmaceutical-co-ltd-class-a-szse-3-c3e852638b7dbf71Pharma Surgeen2026-06-30T05:14:22.000ZPrice to book forward of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class A – SZSE:300357https://www.pharmaradar360.com/article/fda-grants-priority-review-to-roche-s-enspryng-the-first-and-only-at-home-subcut-ebaed64621cc9dd8Pharma Surgeen2026-06-30T05:00:00.000ZFDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)https://www.pharmaradar360.com/article/price-to-book-forward-of-hatinh-pharmaceutical-joint-stock-co-upcom-hdp-87966735aee9471ePharma Surgeen2026-06-30T04:59:25.000ZPrice to book forward of HaTinh Pharmaceutical Joint Stock Co – UPCOM:HDPhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-shanghai-fosun-pharmaceutical-group-co-ltd-class-a-sse-9c712edc31923bf0Pharma Surgeen2026-06-30T04:50:19.000ZPrice to sales forward of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A – SSE:600196https://www.pharmaradar360.com/article/price-to-earnings-forward-of-shanghai-fosun-pharmaceutical-group-co-ltd-class-a-4e339d92ed33a459Pharma Surgeen2026-06-30T04:48:29.000ZPrice to earnings forward of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A – SSE:600196https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-burning-rock-biotech-ltd-sponsored-adr-dus-6-060b041648c696ecPharma Surgeen2026-06-30T04:37:28.000ZEnterprise value to EBIT forward of Burning Rock Biotech Ltd. Sponsored ADR – DUS:6BU0https://www.pharmaradar360.com/article/hong-kong-draws-royalties-giant-as-mainland-china-biotech-licensing-heats-up-abf08a7d3768f156Pharma Surgeen2026-06-30T03:00:12.000ZHong Kong draws royalties giant as mainland China biotech licensing heats uphttps://www.pharmaradar360.com/article/consolidated-financial-statements-for-years-ended-march-31-2026-and-2025-f11b767573b748abPharma Surgeen2026-06-30T03:00:00.000ZConsolidated Financial Statements for Years ended March 31, 2026 and 2025https://www.pharmaradar360.com/article/anzen-revisions-of-precautions-cefcapene-pivoxil-hydrochloride-hydrate-etc-poste-0d804fa20c6b9ae8Pharma Surgeen2026-06-30T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Cefcapene Pivoxil Hydrochloride Hydrate, etc. postedhttps://www.pharmaradar360.com/article/anzen-pmda-alert-for-proper-use-of-drugs-serious-hypocarnitinemia-and-hypoglycae-118b6d6f33bb9cd3Pharma Surgeen2026-06-30T03:00:00.000Z[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) postedhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-susmed-app-for-insomnia-medcle-parti-07745d167fb2bb02Pharma Surgeen2026-06-30T03:00:00.000Z[SHINSA]English Translation of Review Report: SUSMED App for Insomnia Medcle (Partial Change Approval)https://www.pharmaradar360.com/article/legend-biotech-nasdaq-legn-ceo-disposes-shares-to-cover-rsu-tax-d8db950cc8066f7aPharma Surgeen2026-06-30T02:44:13.000ZLegend Biotech (NASDAQ: LEGN) CEO disposes shares to cover RSU taxhttps://www.pharmaradar360.com/article/aci-s-13th-annual-summit-for-women-leaders-in-life-sciences-law-e86b7d799e8f3b06Pharma Surgeen2026-06-30T02:15:19.000ZACI’s 13th Annual Summit for Women Leaders in Life Sciences Lawhttps://www.pharmaradar360.com/article/does-recursion-rxrx-russell-value-index-lift-recast-its-ai-biotech-story-as-deep-13b29570161c0306Pharma Surgeen2026-06-30T02:13:41.000ZDoes Recursion (RXRX) Russell Value Index Lift Recast Its AI Biotech Story as Deep Value?https://www.pharmaradar360.com/article/evaluating-oral-btk-inhibitor-remibrutinib-in-phase-3-study-for-generalized-myas-0a3fb1b1502db443Pharma Surgeen2026-06-30T01:40:38.000ZEvaluating Oral BTK Inhibitor Remibrutinib in Phase 3 Study for Generalized Myasthenia Gravis: The RELIEVE Trialhttps://www.pharmaradar360.com/article/hesso-56-282eb311585a4000Pharma Surgeen2026-06-30T01:07:11.000Z広報誌「hesso（へっそ）」56号を発行しましたhttps://www.pharmaradar360.com/article/compound-pharmacies-are-outrunning-regulations-experts-want-tougher-oversight-a4d199120cadaea9Pharma Surgeen2026-06-30T01:03:50.000ZCompound pharmacies are outrunning regulations. Experts want tougher oversight.https://www.pharmaradar360.com/article/contribution-from-ownership-to-connection-what-bio-usa-says-about-the-next-50-ye-e842ea8e4e5cc0e5Pharma Surgeen2026-06-30T00:35:07.000Z[Contribution] From ownership to connection: What BIO USA says about the next 50 years of biotechhttps://www.pharmaradar360.com/article/abivax-reports-phase-3-ulcerative-colitis-trial-results-by-investing-com-18163fa9a33778f4Pharma Surgeen2026-06-30T00:14:16.000ZAbivax reports phase 3 ulcerative colitis trial results By Investing.comhttps://www.pharmaradar360.com/article/long-term-outcomes-of-adjuvant-metronomic-capecitabine-in-locoregionally-advance-890f648dbd6bc33fPharma Surgeen2026-06-30T00:00:00.000ZLong-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyhttps://www.pharmaradar360.com/article/connectomic-evidence-that-ordered-activity-drives-neuromuscular-network-formatio-043a1c7e99dde4daPharma Surgeen2026-06-30T00:00:00.000ZConnectomic evidence that ordered activity drives neuromuscular network formationhttps://www.pharmaradar360.com/article/author-correction-digital-avatar-therapy-for-distressing-voices-in-psychosis-the-c3af7c5537501514Pharma Surgeen2026-06-30T00:00:00.000ZAuthor Correction: Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trialhttps://www.pharmaradar360.com/article/clinical-decision-support-in-hematological-malignancies-using-a-case-grounded-ai-8a61282da4bf3b4ePharma Surgeen2026-06-30T00:00:00.000ZClinical decision support in hematological malignancies using a case-grounded AI agenthttps://www.pharmaradar360.com/article/multi-antigen-targeting-t-cells-in-pediatric-central-nervous-system-tumors-a-pha-821019a0b82180bePharma Surgeen2026-06-30T00:00:00.000ZMulti-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trialhttps://www.pharmaradar360.com/article/prime-editing-for-precise-genome-engineering-and-modulation-of-fungal-metabolism-166096d5ba74f905Pharma Surgeen2026-06-30T00:00:00.000ZPrime editing for precise genome engineering and modulation of fungal metabolismhttps://www.pharmaradar360.com/article/editor-s-pick-liberate-bio-d9dfa435c8c9ca49Pharma Surgeen2026-06-30T00:00:00.000ZEditor’s pick: Liberate Biohttps://www.pharmaradar360.com/article/editor-s-pick-trogenix-f6934e08bd97400ePharma Surgeen2026-06-30T00:00:00.000ZEditor’s pick: Trogenixhttps://www.pharmaradar360.com/article/ebola-preparedness-must-start-with-ecosystems-and-before-humans-show-symptoms-36b973f5ccc0f341Pharma Surgeen2026-06-30T00:00:00.000ZEbola preparedness must start with ecosystems and before humans show symptomshttps://www.pharmaradar360.com/article/ai-tools-can-speed-up-thinking-but-evidence-still-comes-from-the-lab-bench-cbf0002c6aa8eac8Pharma Surgeen2026-06-30T00:00:00.000ZAI tools can speed up thinking, but evidence still comes from the lab benchhttps://www.pharmaradar360.com/article/child-online-safety-needs-more-than-social-media-bans-a01b6ba517a60e71Pharma Surgeen2026-06-30T00:00:00.000ZChild online safety needs more than social-media banshttps://www.pharmaradar360.com/article/can-rwanda-sustain-its-rise-in-science-and-technology-here-s-what-can-help-fba21fa52e2eece5Pharma Surgeen2026-06-30T00:00:00.000ZCan Rwanda sustain its rise in science and technology? Here’s what can helphttps://www.pharmaradar360.com/article/coffee-is-under-threat-how-scientists-are-fighting-to-save-it-from-extinction-59d95c6e1b94952aPharma Surgeen2026-06-30T00:00:00.000ZCoffee is under threat: how scientists are fighting to save it from extinctionhttps://www.pharmaradar360.com/article/ai-systems-devise-hypotheses-and-ways-to-test-them-e6c02c04612efbcdPharma Surgeen2026-06-30T00:00:00.000ZAI systems devise hypotheses and ways to test themhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-da7e73ee023c2532Pharma Surgeen2026-06-30T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-4c37464e14ef7be1Pharma Surgeen2026-06-30T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-4ea220a4191a14f5Pharma Surgeen2026-06-30T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-968d33f0e4ddb018Pharma Surgeen2026-06-30T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-32aae66a7dca5accPharma Surgeen2026-06-30T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-d1d5cf4213f314f7Pharma Surgeen2026-06-30T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-19740c84cbca5d17Pharma Surgeen2026-06-30T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-d3738f0b72fbbcb2Pharma Surgeen2026-06-30T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-d90a30afbcc099ecPharma Surgeen2026-06-30T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-a1075cdc2077fffaPharma Surgeen2026-06-30T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-c7750e1d3eddd997Pharma Surgeen2026-06-30T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b9466d58512ea8bdPharma Surgeen2026-06-30T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-f0f74d9668cf10ddPharma Surgeen2026-06-30T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-431988b9d9fba7e5Pharma Surgeen2026-06-30T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/proposed-collection-30-day-comment-request-nih-information-collection-forms-to-s-dbef6a57b59d1ea8Pharma Surgeen2026-06-30T00:00:00.000ZProposed Collection; 30-Day Comment Request; NIH Information Collection Forms to Support the Genetic Testing Registry (OD)https://www.pharmaradar360.com/article/world-trade-center-health-program-petitions-024-042-046-047-051-056-058-and-067-2a108a668ae46fb9Pharma Surgeen2026-06-30T00:00:00.000ZWorld Trade Center Health Program; Petitions 024, 042, 046, 047, 051, 056, 058, and 067-Ischemic Heart Disease; Finding of Insufficient Evidencehttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-meeting-58c7a7655aee1fb9Pharma Surgeen2026-06-30T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Meetinghttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-united-states-pharmacopeial-conven-83e4e0cea83ddd7ePharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: United States Pharmacopeial Conventionhttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-veterans-pharmaceuticals-inc-29babdf696c52cd3Pharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: Veterans Pharmaceuticals, Inc.https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-veranova-l-p-4955174adf61e7adPharma Surgeen2026-06-30T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Veranova, L.P.https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-almac-clinical-services-incorp-acs-5a4dda278936ddf2Pharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-catalent-pharma-solutions-llc-e3ea0d45794fb6d2Pharma Surgeen2026-06-30T00:00:00.000ZImporter of Controlled Substances Application: Catalent Pharma Solutions, LLChttps://www.pharmaradar360.com/article/statement-of-organization-functions-and-delegations-of-authority-bfb15c501f69ceddPharma Surgeen2026-06-30T00:00:00.000ZStatement of Organization, Functions, and Delegations of Authorityhttps://www.pharmaradar360.com/article/medical-devices-anesthesiology-devices-classification-of-the-monitor-for-opioid-24ff44f3449b53dcPharma Surgeen2026-06-30T00:00:00.000ZMedical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenationhttps://www.pharmaradar360.com/article/medical-devices-general-and-plastic-surgery-devices-classification-of-the-skin-p-d8cab6002554198cPharma Surgeen2026-06-30T00:00:00.000ZMedical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosishttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-adoption-and-foster-care-a-c6163f61ec0d8f28Pharma Surgeen2026-06-30T00:00:00.000ZSubmission for Office of Management and Budget Review; Adoption and Foster Care Analysis and Reporting System (AFCARS)https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-87c5f79a1e2a8f5dPharma Surgeen2026-06-30T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-f438494877cbd5bdPharma Surgeen2026-06-30T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-d8e1f5e8cb357ffdPharma Surgeen2026-06-30T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/drug-label-update-loperamide-hydrochloride-34f527e2a863fad9Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: Loperamide Hydrochloridehttps://www.pharmaradar360.com/article/drug-label-update-nystatin-c4a3e9d3e9bda5e6Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: NYSTATINhttps://www.pharmaradar360.com/article/erc-proof-of-concept-anslag-till-emma-andersson-ska-leda-till-farre-forsoksdjur-b33467954f3ff73fPharma Surgeen2026-06-30T00:00:00.000ZERC Proof of Concept-anslag till Emma Andersson ska leda till färre försöksdjurhttps://www.pharmaradar360.com/article/adverse-events-after-same-day-covid-19-and-influenza-vaccination-versus-influenz-629d30c80f14db91Pharma Surgeen2026-06-30T00:00:00.000ZAdverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alonehttps://www.pharmaradar360.com/article/clinical-research-progress-of-acupuncture-in-the-treatment-of-post-stroke-should-9a61419ec700cb7dPharma Surgeen2026-06-30T00:00:00.000ZClinical Research Progress of Acupuncture in the Treatment of Post-Stroke Shoulder-Hand Syndromehttps://www.pharmaradar360.com/article/the-role-of-baseline-pao2-fio2-spo2-and-il-6-indicators-in-predicting-in-hospita-457ab042dce97808Pharma Surgeen2026-06-30T00:00:00.000ZThe role of baseline PaO2/FiO2, SpO2 and IL-6 indicators in predicting in-hospital mortality in ARDS patients: a retrospective cohort studyhttps://www.pharmaradar360.com/article/migration-rates-clinical-and-technical-success-for-fixated-compared-to-non-fixat-41f90b400d36f060Pharma Surgeen2026-06-30T00:00:00.000ZMigration Rates, Clinical and Technical Success for Fixated Compared to Non-Fixated Fully Covered Esophageal Self-Expandable Metal Stents (FCSEMS)https://www.pharmaradar360.com/article/alcoholism-research-a-narrative-review-f72aa655d568da71Pharma Surgeen2026-06-30T00:00:00.000ZAlcoholism Research: A Narrative Reviewhttps://www.pharmaradar360.com/article/clinical-evaluation-of-facial-soft-tissue-profile-using-octa-criteria-in-patient-d6a15fbca471dda0Pharma Surgeen2026-06-30T00:00:00.000ZClinical evaluation of facial soft-tissue profile using OCTA criteria in patients: A cross-sectional studyhttps://www.pharmaradar360.com/article/effect-of-silver-diamine-fluoride-versus-fluoride-varnish-in-arresting-early-chi-0f705ae3f5ff6e8aPharma Surgeen2026-06-30T00:00:00.000ZEffect of silver diamine fluoride versus fluoride varnish in arresting early childhood caries: A clinical studyhttps://www.pharmaradar360.com/article/clinical-and-lateral-cephalometric-evaluation-of-class-ii-elastic-therapy-in-ske-e7669a350dca3818Pharma Surgeen2026-06-30T00:00:00.000ZClinical and lateral cephalometric evaluation of class II elastic therapy in skeletal class II malocclusion cases indicated for fixed functional appliance: An in vivo studyhttps://www.pharmaradar360.com/article/dry-needling-versus-kinesiotaping-for-upper-trapezius-trigger-points-a-randomize-2adf6da9e360ab4bPharma Surgeen2026-06-30T00:00:00.000ZDry Needling Versus Kinesiotaping for Upper Trapezius Trigger Points: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/pilot-case-control-study-of-mthfr-c677t-and-mtra2756g-polymorphisms-among-alcoho-ac23fea50c5c4a16Pharma Surgeen2026-06-30T00:00:00.000ZPILOT CASE–CONTROL STUDY OF MTHFR C677T AND MTRA2756G POLYMORPHISMS AMONG ALCOHOL/ TOBACCO USERS IN EASTERN UTTAR PRADESH, INDIA (N = 200)https://www.pharmaradar360.com/article/statistical-optimization-of-amylase-production-by-bacillus-wiedmannii-sppu-4-usi-f3ba7846b3833a9ePharma Surgeen2026-06-30T00:00:00.000ZSTATISTICAL OPTIMIZATION OF AMYLASE PRODUCTION BY BACILLUS WIEDMANNII SPPU 4 USING AGRO-INDUSTRIAL WASTES VIA PLACKETT-BURMAN AND BOX-BEHNKEN DESIGNShttps://www.pharmaradar360.com/article/the-diverse-clinical-presentation-of-mycoplasma-pneumoniae-and-role-of-biofire-f-f4b449c392da71f1Pharma Surgeen2026-06-30T00:00:00.000ZThe Diverse Clinical Presentation of Mycoplasma pneumoniae and Role of BioFire FilmArray Pneumonia Plus Panel: A Case Serieshttps://www.pharmaradar360.com/article/leveraging-statistical-and-machine-learning-techniques-to-enhance-clinical-decis-232629324d8e4f80Pharma Surgeen2026-06-30T00:00:00.000ZLeveraging Statistical and Machine Learning Techniques to Enhance Clinical Decision Support for PID Diagnosishttps://www.pharmaradar360.com/article/ai-enabled-diagnostics-treatment-planning-and-clinical-decision-634d27ef80ddae4aPharma Surgeen2026-06-30T00:00:00.000ZAI-Enabled Diagnostics, Treatment Planning, and Clinical Decisionhttps://www.pharmaradar360.com/article/fuzzy-neural-framework-for-clinical-safety-evaluation-of-medical-large-language-a4b05e443a7ab1b5Pharma Surgeen2026-06-30T00:00:00.000ZFuzzy Neural Framework for Clinical Safety Evaluation of Medical Large Language Modelshttps://www.pharmaradar360.com/article/boron-neutron-capture-therapy-for-recurrent-pediatric-sialoblastoma-the-first-cl-f2b6238e758d6d17Pharma Surgeen2026-06-30T00:00:00.000ZBoron neutron capture therapy for recurrent pediatric sialoblastoma: the first clinical experience and dosimetric considerations for skeletal safety with 4-year follow-uphttps://www.pharmaradar360.com/article/the-use-of-antihypertensive-drugs-in-pre-dialysis-chronic-kidney-disease-patient-449737fe248ec59aPharma Surgeen2026-06-30T00:00:00.000ZThe Use of Antihypertensive Drugs in Pre-Dialysis Chronic Kidney Disease Patientshttps://www.pharmaradar360.com/article/efficacy-of-escin-combined-with-micronized-purified-flavonoid-fraction-in-contro-836aefbcd61b61c8Pharma Surgeen2026-06-30T00:00:00.000ZEfficacy of escin combined with micronized purified flavonoid fraction in controlling bleeding and preventing recurrence of acute internal hemorrhoids: a randomized controlled trialhttps://www.pharmaradar360.com/article/new-perspectives-on-cutaneous-and-sexually-transmitted-infections-clinical-epide-268bcc399dcc1cc2Pharma Surgeen2026-06-30T00:00:00.000ZNew Perspectives on Cutaneous and Sexually Transmitted Infections: Clinical, Epidemiological, and Therapeutic Updateshttps://www.pharmaradar360.com/article/from-migration-to-emergency-a-systematic-review-of-acute-presentations-following-5931acac4cd6707bPharma Surgeen2026-06-30T00:00:00.000ZFrom Migration to Emergency: A Systematic Review of Acute Presentations Following Late Esophageal Stent Migrationhttps://www.pharmaradar360.com/article/saferx-a-canonical-pharmaceutical-knowledge-integration-framework-for-multimodal-953230d40d3d2dd6Pharma Surgeen2026-06-30T00:00:00.000ZSafeRx: A Canonical Pharmaceutical Knowledge Integration Framework for Multimodal Medication Safetyhttps://www.pharmaradar360.com/article/lung-cancer-organoids-for-functional-precision-oncology-from-disease-modeling-to-15e5f3a927ad1d43Pharma Surgeen2026-06-30T00:00:00.000ZLung cancer organoids for functional precision oncology: from disease modeling to clinical decision supporthttps://www.pharmaradar360.com/article/long-term-stability-of-maxillary-protraction-in-severe-class-iii-cases-distracti-3caf955dd54d61fbPharma Surgeen2026-06-30T00:00:00.000ZLong-Term Stability of Maxillary Protraction in Severe Class III Cases: Distraction Osteogenesis vs. Prolonged Facemask Usehttps://www.pharmaradar360.com/article/comparative-evaluation-of-fetomaternal-outcome-in-gestational-thrombocytopenia-w-73f59122cb0b0198Pharma Surgeen2026-06-30T00:00:00.000ZComparative Evaluation of Fetomaternal Outcome in Gestational Thrombocytopenia with Thrombocytopenia Due to Hypertensive Disorders of Pregnancyhttps://www.pharmaradar360.com/article/long-term-clinical-outcomes-of-radiofrequency-ablation-for-pathologically-diagno-1fb5280917bba4acPharma Surgeen2026-06-30T00:00:00.000ZLong-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experiencehttps://www.pharmaradar360.com/article/transnasal-humidified-rapid-insufflation-ventilatory-exchange-in-preoperative-hy-18b6136ecd91c2e4Pharma Surgeen2026-06-30T00:00:00.000ZTransnasal Humidified Rapid-Insufflation Ventilatory Exchange in Preoperative Hypoxemic Patients During General Anesthesia Induction and Recovery: A Prospective Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-practice-guideline-recommendations-for-orthopedic-surgical-management-o-4a1b0b6924126505Pharma Surgeen2026-06-30T00:00:00.000ZClinical practice guideline recommendations for orthopedic surgical management of traumatic hip fractures: a systematic reviewhttps://www.pharmaradar360.com/article/evaluation-of-admission-level-clinical-laboratory-and-vascular-imaging-predictor-19e65d974bb4785ePharma Surgeen2026-06-30T00:00:00.000ZEvaluation of admission-level clinical, laboratory, and vascular imaging predictors of prolonged length of stay in acute ischemic strokehttps://www.pharmaradar360.com/article/geriatric-case-report-presenting-an-alzheimer-s-disease-patient-with-polypharmac-a72c110235825da8Pharma Surgeen2026-06-30T00:00:00.000ZGeriatric Case Report Presenting an Alzheimer’s Disease Patient with Polypharmacy Resulting in Significant Drug-Drug Interactionhttps://www.pharmaradar360.com/article/a-study-on-the-block-size-and-response-variables-determination-of-mbsd-in-the-mi-e821434bf523d773Pharma Surgeen2026-06-30T00:00:00.000ZA Study on the Block Size and Response Variables Determination of MBSD in the Mixing Processhttps://www.pharmaradar360.com/article/comparative-review-of-reimbursement-and-payment-models-for-gene-therapies-and-th-fe86c726b6e4aa4dPharma Surgeen2026-06-30T00:00:00.000ZComparative Review of Reimbursement and Payment Models for Gene Therapies and Their Policy Implicationshttps://www.pharmaradar360.com/article/renal-dysfunction-as-a-marker-of-adverse-outcomes-in-early-sepsis-in-the-emergen-ddab46eeffb3bac2Pharma Surgeen2026-06-30T00:00:00.000ZRenal dysfunction as a marker of adverse outcomes in early sepsis in the emergency departmenthttps://www.pharmaradar360.com/article/the-most-common-airway-foreign-bodies-removed-with-an-anti-choking-suction-devic-64d9c5837da2e1d1Pharma Surgeen2026-06-30T00:00:00.000ZThe most common airway foreign bodies removed with an anti-choking suction device: a descriptive retrospective studyhttps://www.pharmaradar360.com/article/recommendations-for-optimizing-the-use-of-dysmorphic-red-blood-cell-counts-in-th-149cb0b431125542Pharma Surgeen2026-06-30T00:00:00.000ZRecommendations for optimizing the use of dysmorphic red blood cell counts in the clinical laboratoryhttps://www.pharmaradar360.com/article/adjunctive-effects-of-combined-lacticaseibacillus-rhamnosus-dm163-and-lactobacil-dfc2b34a1c7e0c1cPharma Surgeen2026-06-30T00:00:00.000ZAdjunctive effects of combined Lacticaseibacillus rhamnosus DM163 and Lactobacillus plantarum DSR920 following scaling and root planing in patients with mild gingivitis: a randomized, double-blind pilot clinical trialhttps://www.pharmaradar360.com/article/oral-hygiene-behaviors-and-perceptions-of-tooth-gem-wearers-focusing-on-oral-hyg-8ec4583d5a3d468cPharma Surgeen2026-06-30T00:00:00.000ZOral Hygiene Behaviors and Perceptions of Tooth Gem Wearers: Focusing on Oral Hygiene Care Educational Experiencehttps://www.pharmaradar360.com/article/associations-between-tongue-coating-biofluorescence-and-oral-health-behaviors-in-06c34919ee02a9c9Pharma Surgeen2026-06-30T00:00:00.000ZAssociations between Tongue-Coating Biofluorescence and Oral Health Behaviors in Dental Hygiene Studentshttps://www.pharmaradar360.com/article/medical-devices-used-in-cystic-fibrosis-ba1e8def90838492Pharma Surgeen2026-06-30T00:00:00.000ZMedical Devices Used in Cystic Fibrosishttps://www.pharmaradar360.com/article/cross-sectional-and-longitudinal-associations-of-activity-diversity-with-physica-0b86b09829539f0ePharma Surgeen2026-06-30T00:00:00.000ZCross-sectional and longitudinal associations of activity diversity with physical function in community-dwelling older adultshttps://www.pharmaradar360.com/article/exploring-scolymus-hispanicus-l-leaves-as-a-source-of-natural-therapeutics-nutri-b9b7fd7b8cdda33dPharma Surgeen2026-06-30T00:00:00.000ZExploring Scolymus hispanicus L. leaves as a source of natural therapeutics: nutritional, phytochemical, and pharmacological evaluationshttps://www.pharmaradar360.com/article/youngshin-kwak-head-of-oscotec-research-institute-we-will-compete-with-anti-resi-95349ea263296f7aPharma Surgeen2026-06-29T23:42:46.000ZYoungshin Kwak, Head of Oscotec Research Institute: "We Will Compete with Anti-Resistance Cancer Therapy Within 3 Years" [BioUSA]https://www.pharmaradar360.com/article/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-fa-adacb7c3e846f7c0Pharma Surgeen2026-06-29T23:31:47.000ZFDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.https://www.pharmaradar360.com/article/advancing-perioperative-ultrasound-dr-deepak-borde-on-ai-and-echoliteracy-574318964655b176Pharma Surgeen2026-06-29T23:20:10.000ZAdvancing Perioperative Ultrasound: Dr. Deepak Borde on AI and Echoliteracyhttps://www.pharmaradar360.com/article/uk-s-first-maternity-and-neonatal-commissioner-to-be-appointed-44be2a8848cf9ec7Pharma Surgeen2026-06-29T23:05:00.000ZUK’s first Maternity and Neonatal Commissioner to be appointedhttps://www.pharmaradar360.com/article/cellid-crashes-after-hours-on-phase-3-failure-shaperon-dives-25-k-bio-pulse-109ea09c1935f4f8Pharma Surgeen2026-06-29T23:02:02.000ZCellid Crashes After-Hours on Phase 3 Failure...Shaperon Dives 25%[K-bio pulse]https://www.pharmaradar360.com/article/la-unlp-en-el-lanzamiento-de-un-programa-de-formacion-legislativa-f8395c6807c7a832Pharma Surgeen2026-06-29T22:24:59.000ZLa UNLP en el lanzamiento de un programa de formación legislativahttps://www.pharmaradar360.com/article/la-unlp-fortalece-vinculos-academicos-y-culturales-con-turquia-6327a16c667a5f0fPharma Surgeen2026-06-29T22:24:57.000ZLa UNLP fortalece vínculos académicos y culturales con Turquíahttps://www.pharmaradar360.com/article/french-biotech-company-ipsen-to-buy-kartos-therapeutics-for-450-million-d604fc61f0bdb53ePharma Surgeen2026-06-29T22:02:39.000ZFrench biotech company Ipsen to buy Kartos Therapeutics for $450 millionhttps://www.pharmaradar360.com/article/acrp-fellow-says-profession-s-future-is-bright-for-those-willing-to-embrace-chan-459ca75dc627eefdPharma Surgeen2026-06-29T21:20:54.000ZACRP Fellow Says Profession’s Future is “Bright for Those Willing to Embrace Change”https://www.pharmaradar360.com/article/biotech-is-the-rate-cut-trade-in-disguise-4c28e3ed5618f261Pharma Surgeen2026-06-29T21:20:00.000ZBiotech Is The Rate Cut Trade In Disguisehttps://www.pharmaradar360.com/article/medicaid-work-requirements-nord-resources-statements-implementation-tools-36d60e86b82e5a47Pharma Surgeen2026-06-29T21:15:26.000ZMedicaid Work Requirements: NORD Resources, Statements & Implementation Toolshttps://www.pharmaradar360.com/article/first-time-market-entry-challenges-how-to-get-it-right-with-fsp-support-67edbe958c0d5933Pharma Surgeen2026-06-29T20:59:42.000ZFirst-time market entry challenges: How to get it right with FSP supporthttps://www.pharmaradar360.com/article/carolina-creates-a-capital-classroom-in-dc-5dc67dbc7e1bb015Pharma Surgeen2026-06-29T20:46:07.000ZCarolina creates a capital classroom in DChttps://www.pharmaradar360.com/article/fda-extends-praxis-nasdaq-prax-relutrigine-review-deadline-to-dec-27-2026-e9afc2d37278672bPharma Surgeen2026-06-29T20:41:20.000ZFDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026https://www.pharmaradar360.com/article/silo-pharma-advances-spc-15-ptsd-therapeutic-with-drug-device-robustness-study-a-2401168cbede3db9Pharma Surgeen2026-06-29T20:34:51.000ZSilo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Requesthttps://www.pharmaradar360.com/article/maharashtra-fda-suspends-licences-of-6-mumbai-eateries-over-rat-infestation-expi-e943dbbce32a8f71Pharma Surgeen2026-06-29T20:31:59.000ZMaharashtra FDA Suspends Licences Of 6 Mumbai Eateries Over Rat Infestation, Expired Food, And Unhygienichttps://www.pharmaradar360.com/article/fda-s-drug-repurposing-initiative-signals-a-shift-in-regulatory-strategy-0ed3d8837553b0d6Pharma Surgeen2026-06-29T20:30:15.000ZFDA’s Drug Repurposing Initiative Signals a Shift in Regulatory Strategyhttps://www.pharmaradar360.com/article/biomass-magazine-why-use-living-cells-nlr-is-making-chemicals-with-enzymes-alone-9a28d5062fd3739aPharma Surgeen2026-06-29T20:26:00.000ZBiomass Magazine: Why Use Living Cells? NLR Is Making Chemicals With Enzymes Alonehttps://www.pharmaradar360.com/article/repurposing-hiv-drugs-to-fight-alzheimer-s-b226e458299e397dPharma Surgeen2026-06-29T20:25:26.000ZRepurposing HIV drugs to fight Alzheimer’shttps://www.pharmaradar360.com/article/pbm-lobby-goes-on-the-offensive-d8b96fddf8fd0b17Pharma Surgeen2026-06-29T20:22:00.000ZPBM lobby goes on the offensivehttps://www.pharmaradar360.com/article/the-eu-s-biotech-act-part-2-compelling-changes-to-clinical-trial-regulation-4b54038c83047287Pharma Surgeen2026-06-29T20:17:32.000ZThe EU’s Biotech Act (Part 2): compelling changes to clinical trial regulationhttps://www.pharmaradar360.com/article/silo-pharma-tests-nasal-spray-device-for-ptsd-drug-ahead-of-fda-meeting-33e82a1d532dc2b3Pharma Surgeen2026-06-29T20:15:00.000ZSilo Pharma tests nasal spray device for PTSD drug ahead of FDA meetinghttps://www.pharmaradar360.com/article/abbvie-announces-positive-phase-3-results-for-epcoritamab-plus-lenalidomide-in-p-a44c6c3e5189d1c0Pharma Surgeen2026-06-29T20:15:00.000ZAbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphomahttps://www.pharmaradar360.com/article/abivax-s-ulcerative-colitis-drug-shows-benefit-in-hard-to-treat-patients-96baac148c3d1be8Pharma Surgeen2026-06-29T20:05:00.000ZAbivax’s ulcerative colitis drug shows benefit in hard-to-treat patientshttps://www.pharmaradar360.com/article/faculty-promotions-5704f7b7f8f6b13dPharma Surgeen2026-06-29T20:03:44.000ZFaculty promotionshttps://www.pharmaradar360.com/article/unmc-student-brings-alzheimer-s-research-to-national-hackathon-at-allen-institut-63bf1bf55f607beePharma Surgeen2026-06-29T19:58:03.000ZUNMC student brings Alzheimer’s research to national hackathon at Allen Institutehttps://www.pharmaradar360.com/article/ipsen-s-450m-deal-brings-drug-that-could-make-a-standard-blood-cancer-therapy-be-170f3cbb2ec1bd22Pharma Surgeen2026-06-29T19:57:58.000ZIpsen’s $450M Deal Brings Drug That Could Make a Standard Blood Cancer Therapy Betterhttps://www.pharmaradar360.com/article/resident-doctors-agree-deal-with-government-to-end-strikes-f992035bf377e716Pharma Surgeen2026-06-29T19:27:00.000ZResident doctors agree deal with government to end strikeshttps://www.pharmaradar360.com/article/vancouver-biotech-zymeworks-buying-theravance-for-us-929m-3a6ce40027c9c419Pharma Surgeen2026-06-29T19:27:00.000ZVancouver biotech Zymeworks buying Theravance for US$929Mhttps://www.pharmaradar360.com/article/dea-and-fda-highlight-how-marijuana-is-safer-than-alcohol-and-opioids-during-res-d3048c8a476c9881Pharma Surgeen2026-06-29T19:26:19.000ZDEA And FDA Highlight How Marijuana Is Safer Than Alcohol And Opioids During Rescheduling Hearing's Opening Dayhttps://www.pharmaradar360.com/article/gerren-mcham-what-effective-pharma-reshoring-actually-requires-603e11dd72cd561aPharma Surgeen2026-06-29T19:18:53.000ZGerren McHam: What Effective Pharma Reshoring Actually Requireshttps://www.pharmaradar360.com/article/unmc-department-of-anesthesiology-celebrates-class-of-2026-at-annual-graduation-3d15e5b2cd6f9a82Pharma Surgeen2026-06-29T19:12:20.000ZUNMC Department of Anesthesiology celebrates class of 2026 at annual graduation ceremonyhttps://www.pharmaradar360.com/article/nearly-four-million-medicare-beneficiaries-could-be-eligible-for-the-temporary-m-f1d7cc9f6b86b0bcPharma Surgeen2026-06-29T19:00:00.000ZNearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program Covering These Drugs for Weight Losshttps://www.pharmaradar360.com/article/two-mit-faculty-members-named-2026-pew-biomedical-scholars-4eb913c562175779Pharma Surgeen2026-06-29T19:00:00.000ZTwo MIT faculty members named 2026 Pew Biomedical Scholarshttps://www.pharmaradar360.com/article/uncy-stock-rallies-8-as-retail-traders-anticipate-fda-clearance-for-lead-drug-ca-374992be2f082ddaPharma Surgeen2026-06-29T18:57:00.000ZUNCY Stock Rallies 8% As Retail Traders Anticipate FDA Clearance For Lead Drug Candidatehttps://www.pharmaradar360.com/article/cale-kassel-md-named-director-to-nebraska-society-of-anesthesiologists-efbabe31bbaf127bPharma Surgeen2026-06-29T18:56:16.000ZCale Kassel, MD, named director to Nebraska Society of Anesthesiologistshttps://www.pharmaradar360.com/article/unmc-department-of-anesthesiology-joins-national-oxygen-trial-6d8cd22537c4435dPharma Surgeen2026-06-29T18:43:49.000ZUNMC Department of Anesthesiology joins national oxygen trialhttps://www.pharmaradar360.com/article/tennessee-plans-to-share-data-on-children-with-disabilities-with-immigration-aut-8eb3f08506aab344Pharma Surgeen2026-06-29T18:28:55.000ZTennessee Plans to Share Data on Children with Disabilities with Immigration Authoritieshttps://www.pharmaradar360.com/article/ipsen-enters-merger-agreement-to-acquire-kartos-therapeutics-pharmexec-f203328ea22ef06fPharma Surgeen2026-06-29T18:27:18.000ZIpsen Enters Merger Agreement to Acquire Kartos Therapeutics | PharmExechttps://www.pharmaradar360.com/article/sagimet-biosciences-added-to-russell-2000-and-3000-indexes-343c791da7678659Pharma Surgeen2026-06-29T18:18:55.000ZSagimet Biosciences added to Russell 2000 and 3000 indexeshttps://www.pharmaradar360.com/article/comp360-rems-and-what-fda-psychedelic-approval-path-means-for-investors-and-oper-c63079f9b4927307Pharma Surgeen2026-06-29T18:15:15.000ZCOMP360, REMS and What FDA Psychedelic Approval Path Means for Investors and Operatorshttps://www.pharmaradar360.com/article/scientists-discover-an-unexpected-way-to-make-pancreatic-cancer-cells-self-destr-89eef67693059693Pharma Surgeen2026-06-29T18:08:33.000ZScientists discover an unexpected way to make pancreatic cancer cells self-destructhttps://www.pharmaradar360.com/article/pediatric-clinical-trial-update-q2-2026-6f63cf54518f8524Pharma Surgeen2026-06-29T18:01:24.000ZPediatric clinical trial update: Q2 2026https://www.pharmaradar360.com/article/nearly-four-million-medicare-beneficiaries-met-the-eligibility-criteria-in-2023-a48e1d0c734ff734Pharma Surgeen2026-06-29T17:59:01.000ZNearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridgehttps://www.pharmaradar360.com/article/maharashtra-orders-statewide-blood-bank-inspection-drive-after-fda-crackdown-on-a63c596b26ddd641Pharma Surgeen2026-06-29T17:52:17.000ZMaharashtra Orders Statewide Blood Bank Inspection Drive After FDA Crackdown On Safety Violationshttps://www.pharmaradar360.com/article/biomedical-engineers-send-cartilage-tissue-experiment-to-outer-space-54926680a6d1530fPharma Surgeen2026-06-29T17:51:47.000ZBiomedical engineers send cartilage tissue experiment to outer spacehttps://www.pharmaradar360.com/article/the-biotech-winter-finally-thaws-e8d08d0ed239b278Pharma Surgeen2026-06-29T17:37:27.000ZThe Biotech Winter Finally Thawshttps://www.pharmaradar360.com/article/healthy-but-sedentary-individuals-show-early-decline-in-cellular-energy-producti-786f9a8bd70d66dbPharma Surgeen2026-06-29T17:33:17.000ZHealthy but Sedentary Individuals Show Early Decline in Cellular Energy Productionhttps://www.pharmaradar360.com/article/fda-issues-complete-response-letter-to-sobi-s-nasp-for-gout-a6241daad60686edPharma Surgeen2026-06-29T17:31:57.000ZFDA issues complete response letter to Sobi’s NASP for gouthttps://www.pharmaradar360.com/article/lilly-s-jaypirca-receives-chmp-positive-opinion-for-cll-in-europe-29b9738d254033f2Pharma Surgeen2026-06-29T17:31:57.000ZLilly’s Jaypirca receives CHMP positive opinion for CLL in Europehttps://www.pharmaradar360.com/article/connecting-histories-e11637e4229093abPharma Surgeen2026-06-29T17:23:39.000ZConnecting historieshttps://www.pharmaradar360.com/article/why-i-m-eyeing-prices-biotech-and-ai-in-q3-ce2e13cb98988f3ePharma Surgeen2026-06-29T16:45:00.000ZWhy I’m Eyeing Prices, Biotech and AI in Q3https://www.pharmaradar360.com/article/kff-tracker-america-first-mou-bilateral-global-health-agreements-99609d7d72be321fPharma Surgeen2026-06-29T16:37:12.000ZKFF Tracker: America First MOU Bilateral Global Health Agreementshttps://www.pharmaradar360.com/article/why-natera-s-prospera-could-reshape-how-eledon-measures-kidney-transplant-injury-80cc74f8855cc610Pharma Surgeen2026-06-29T16:23:32.000ZWhy Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3.https://www.pharmaradar360.com/article/growing-scientific-evidence-links-e-cigarette-chemicals-to-heart-health-risks-d51138f802c9ba14Pharma Surgeen2026-06-29T16:00:00.000ZGrowing scientific evidence links e-cigarette chemicals to heart health riskshttps://www.pharmaradar360.com/article/biodexa-pharmaceuticals-bdrx-expands-phase-3-clinical-trial-to-canada-b51c749aad11da21Pharma Surgeen2026-06-29T15:56:15.000ZBiodexa Pharmaceuticals (BDRX) Expands Phase 3 Clinical Trial to Canadahttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9Pharma Surgeen2026-06-29T15:56:09.000ZCover of vaccination evaluated rapidly (COVER) programme 2025 to 2026: quarterly datahttps://www.pharmaradar360.com/article/warming-streams-are-pushing-young-salmon-beyond-their-limits-new-research-d71a34a19441c388Pharma Surgeen2026-06-29T15:55:00.000ZWarming streams are pushing young salmon beyond their limits: new researchhttps://www.pharmaradar360.com/article/health-protection-report-current-issue-and-latest-surveillance-reports-5ed3a5edbdab3b1aPharma Surgeen2026-06-29T15:53:41.000ZHealth Protection Report: current issue and latest surveillance reportshttps://www.pharmaradar360.com/article/vaccine-uptake-guidance-and-the-latest-coverage-data-35c22e77947ea440Pharma Surgeen2026-06-29T15:53:17.000ZVaccine uptake guidance and the latest coverage datahttps://www.pharmaradar360.com/article/efpia-urges-innovation-friendly-approach-in-submission-on-eu-biotech-act-ii-b5908d054f3bea74Pharma Surgeen2026-06-29T15:22:30.000ZEFPIA urges innovation-friendly approach in submission on EU Biotech Act IIhttps://www.pharmaradar360.com/article/guidance-borderline-products-medical-devices-and-other-products-3e47418eda21a643Pharma Surgeen2026-06-29T15:20:59.000ZGuidance: Borderline products: medical devices and other productshttps://www.pharmaradar360.com/article/oportunidades-de-estudio-e-investigacion-en-alemania-y-francia-daad-y-campus-fra-d9ce9272f0a4a758Pharma Surgeen2026-06-29T15:20:48.000ZOportunidades de estudio e investigación en Alemania y Francia (DAAD y Campus France)https://www.pharmaradar360.com/article/biotech-bigwigs-abbv-jnj-biib-lly-hit-new-52-week-highs-2cfff0326a536717Pharma Surgeen2026-06-29T15:10:00.000ZBiotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highshttps://www.pharmaradar360.com/article/what-s-standing-between-reshoring-ambitions-and-reality-ad69be0976d691e1Pharma Surgeen2026-06-29T15:08:48.000ZWhat's Standing Between Reshoring Ambitions and Reality?https://www.pharmaradar360.com/article/shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd-class-h-2def001393d0942dPharma Surgeen2026-06-29T15:08:30.000ZShanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class Hhttps://www.pharmaradar360.com/article/fda-rejects-sobi-s-gout-drug-over-manufacturing-issues-sparing-amgen-blockbuster-86ea236e23717550Pharma Surgeen2026-06-29T15:04:30.000ZFDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbusterhttps://www.pharmaradar360.com/article/new-york-and-oregon-researchers-to-lead-pioneering-cardiac-arrest-studies-b54a9099b6010413Pharma Surgeen2026-06-29T15:00:00.000ZNew York and Oregon researchers to lead pioneering cardiac arrest studieshttps://www.pharmaradar360.com/article/tnvitamins-moringa-supplement-recall-issued-over-salmonella-risk-fda-says-0649d285c346bb7aPharma Surgeen2026-06-29T14:50:29.000ZTNVitamins moringa supplement recall issued over salmonella risk, FDA sayshttps://www.pharmaradar360.com/article/shoulder-innovations-announces-closing-of-up-to-50-million-credit-facility-cc873046ca2639afPharma Surgeen2026-06-29T14:42:26.000ZShoulder Innovations Announces Closing of up to $50 Million Credit Facilityhttps://www.pharmaradar360.com/article/boletin-de-posgrado-0b50ac8e977e1d60Pharma Surgeen2026-06-29T14:40:54.000ZBoletín de Posgradohttps://www.pharmaradar360.com/article/syre-and-spyre-ride-new-ibd-trends-in-biotech-drug-design-e12fb7047c38de30Pharma Surgeen2026-06-29T14:37:30.000ZSYRE and Spyre Ride New IBD Trends in Biotech Drug Designhttps://www.pharmaradar360.com/article/alpha-1-antitrypsin-gene-editing-startup-raises-230-million-serapha-bio-aatd-deb-c1ddae6fe10c7014Pharma Surgeen2026-06-29T14:37:30.000ZAlpha-1 Antitrypsin Gene Editing Startup Raises $230 Million: Serapha Bio AATD Debuthttps://www.pharmaradar360.com/article/biodexa-pharmaceuticals-bdrx-expands-phase-3-clinical-trial-to-canada-9f9d4d710667f7f6Pharma Surgeen2026-06-29T14:34:01.000ZBiodexa Pharmaceuticals (BDRX) Expands Phase 3 Clinical Trial to Canadahttps://www.pharmaradar360.com/article/biotech-spac-deal-gets-it-to-nasdaq-astrazeneca-phase-3-win-in-children-s-bone-d-8042a7ad4bfd70f0Pharma Surgeen2026-06-29T14:34:00.000ZBiotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone diseasehttps://www.pharmaradar360.com/article/latest-winner-in-our-research-is-beautiful-competition-77650e71a03bc651Pharma Surgeen2026-06-29T14:27:26.000ZLatest winner in our Research is Beautiful competitionhttps://www.pharmaradar360.com/article/pmcf-survey-vs-clinical-investigation-greenlight-guru-caeedc90404e8228Pharma Surgeen2026-06-29T14:19:57.000ZPMCF survey vs clinical investigation | Greenlight Guruhttps://www.pharmaradar360.com/article/compras-y-contrataciones-5f361c281bd07c9dPharma Surgeen2026-06-29T14:16:30.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/larimar-stock-slides-15-despite-fda-backing-rolling-submission-for-rare-disease-ff1e82132cd422e0Pharma Surgeen2026-06-29T14:15:41.000ZLarimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drughttps://www.pharmaradar360.com/article/dcoy-stock-explodes-higher-as-volatile-biotech-trading-heats-up-e67b19e3709f5d09Pharma Surgeen2026-06-29T14:03:00.000ZDCOY Stock Explodes Higher As Volatile Biotech Trading Heats Uphttps://www.pharmaradar360.com/article/evommune-s-phase-2b-trial-flops-ending-challenge-to-novartis-in-hives-c54492e591d5e90cPharma Surgeen2026-06-29T14:00:00.000ZEvommune’s phase 2b trial flops, ending challenge to Novartis in hiveshttps://www.pharmaradar360.com/article/talawar-tx-launches-as-publicly-traded-biotech-d51a011b0086d422Pharma Surgeen2026-06-29T13:58:37.000ZTalawar Tx launches as publicly traded biotechhttps://www.pharmaradar360.com/article/klinik-salem-startet-zum-1-juli-2026-als-teil-des-universitatsklinikums-heidelbe-a557897c2f1294f7Pharma Surgeen2026-06-29T13:55:53.000ZKlinik Salem startet zum 1. Juli 2026 als Teil des Universitätsklinikums Heidelberghttps://www.pharmaradar360.com/article/talawar-bets-bispecific-approach-can-shake-up-eczema-market-51bfde1fb223cd90Pharma Surgeen2026-06-29T13:54:31.000ZTalawar bets bispecific approach can shake up eczema markethttps://www.pharmaradar360.com/article/pro-life-states-get-victory-against-mail-order-abortions-in-appeals-court-ruling-82b2073b504322b5Pharma Surgeen2026-06-29T13:51:00.000ZPro-Life States Get Victory Against Mail-Order Abortions in Appeals Court Rulinghttps://www.pharmaradar360.com/article/visiting-faculty-program-2027-2028-en-sciences-po-francia-34c157a7f46da6bcPharma Surgeen2026-06-29T13:41:39.000ZVisiting Faculty Program 2027-2028 en Sciences Po (Francia)https://www.pharmaradar360.com/article/national-formulary-will-make-shortages-worse-suggests-npa-chair-80376c8ce2a6f738Pharma Surgeen2026-06-29T13:40:50.000ZNational formulary will make shortages worse, suggests NPA chairhttps://www.pharmaradar360.com/article/glasgow-s-first-gp-walk-in-service-opened-by-first-minister-955e1f187929023fPharma Surgeen2026-06-29T13:37:30.000ZGlasgow’s first GP walk-in service opened by First Ministerhttps://www.pharmaradar360.com/article/genentech-adjacent-japanese-drugmaker-sets-up-peninsula-office-looks-for-deals-34e509706746812ePharma Surgeen2026-06-29T13:34:00.000ZGenentech-adjacent Japanese drugmaker sets up Peninsula office, looks for dealshttps://www.pharmaradar360.com/article/lycia-raises-75m-as-degrader-pipeline-moves-toward-patient-data-1357a02f49fb6712Pharma Surgeen2026-06-29T13:32:07.000ZLycia raises $75m as degrader pipeline moves toward patient datahttps://www.pharmaradar360.com/article/united-therapeutics-nabs-fda-approval-for-donor-lung-assessment-device-7549999e6066271cPharma Surgeen2026-06-29T13:27:06.000ZUnited Therapeutics nabs FDA approval for donor-lung assessment devicehttps://www.pharmaradar360.com/article/overview-of-president-trump-s-executive-actions-impacting-lgbtq-health-8ce0802d1454678cPharma Surgeen2026-06-29T13:27:00.000ZOverview of President Trump’s Executive Actions Impacting LGBTQ+ Healthhttps://www.pharmaradar360.com/article/the-achilles-heel-of-research-e984da872a291000Pharma Surgeen2026-06-29T13:23:49.000ZThe Achilles’ Heel of Researchhttps://www.pharmaradar360.com/article/nashik-fda-warns-food-businesses-of-strict-action-over-safety-violations-says-no-05c930537677e143Pharma Surgeen2026-06-29T13:21:28.000ZNashik: FDA Warns Food Businesses Of Strict Action Over Safety Violations; Says No Compromise On Public Healthhttps://www.pharmaradar360.com/article/proteine-animali-o-proteine-vegetali-le-differenze-nutrizionali-1a3c63e66658e2e0Pharma Surgeen2026-06-29T13:19:43.000ZProteine animali o proteine vegetali: le differenze nutrizionalihttps://www.pharmaradar360.com/article/4d-molecular-fdmt-completes-enrollment-for-phase-3-clinical-tr-f46c9c69b827c846Pharma Surgeen2026-06-29T13:09:24.000Z4D Molecular (FDMT) Completes Enrollment for Phase 3 Clinical Trhttps://www.pharmaradar360.com/article/biotech-pre-market-pulse-upc-dcoy-juns-post-sharp-moves-65bf894055c16d0dPharma Surgeen2026-06-29T13:06:00.000ZBiotech Pre-Market Pulse: UPC, DCOY, JUNS Post Sharp Moveshttps://www.pharmaradar360.com/article/fda-approves-covid-19-antiviral-xocova-as-pep-but-will-it-be-accessible-bec5d835b47cdd8ePharma Surgeen2026-06-29T13:05:47.000ZFDA Approves COVID-19 Antiviral Xocova as PEP. But Will It Be Accessible?https://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-ebaf55cc34bc8968Pharma Surgeen2026-06-29T12:59:11.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: Related Resourceshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-07c5251db81a9a2ePharma Surgeen2026-06-29T12:59:06.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: 1115-waivershttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-9bc67f08bc181474Pharma Surgeen2026-06-29T12:59:01.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Implementation Questionshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-9eae144668101452Pharma Surgeen2026-06-29T12:58:56.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirementshttps://www.pharmaradar360.com/article/replimune-gets-fda-review-for-melanoma-drug-after-prior-setbacks-48400ba9ef61b731Pharma Surgeen2026-06-29T12:58:22.000ZReplimune gets FDA review for melanoma drug after prior setbackshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-8914656093d5fdaePharma Surgeen2026-06-29T12:58:10.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Data and Policieshttps://www.pharmaradar360.com/article/krystal-biotech-krys-soars-3-4-is-further-upside-left-in-the-stock-3fa085195064a416Pharma Surgeen2026-06-29T12:49:00.000ZKrystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?https://www.pharmaradar360.com/article/first-patients-treated-via-fda-cleared-transcranial-magnetic-stimulation-plus-fd-30cf6559ace66032Pharma Surgeen2026-06-29T12:46:16.000ZFirst Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)https://www.pharmaradar360.com/article/helus-pharma-reports-phase-3-trial-progress-closes-50m-offering-by-investing-com-860e733cb718de8dPharma Surgeen2026-06-29T12:37:21.000ZHelus Pharma reports Phase 3 trial progress, closes $50M offering By Investing.comhttps://www.pharmaradar360.com/article/us-fda-has-granted-a-rare-pediatric-disease-drug-designation-for-nv-387-as-a-tre-3ce828faac2595ccPharma Surgeen2026-06-29T12:35:03.000ZUS FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucherhttps://www.pharmaradar360.com/article/biodexa-s-fap-trial-expands-into-canada-as-enrolment-hits-73-c76fbefbb02b212aPharma Surgeen2026-06-29T12:30:00.000ZBiodexa's FAP trial expands into Canada as enrolment hits 73https://www.pharmaradar360.com/article/fda-rare-pediatric-disease-designation-could-speed-a-measles-drug-review-5679299767b44a65Pharma Surgeen2026-06-29T12:30:00.000ZFDA rare pediatric disease designation could speed a measles drug reviewhttps://www.pharmaradar360.com/article/faire-du-calme-un-allie-du-soin-c-est-l-ambition-du-projet-rea-silencieuse-6e46160f2b78ead7Pharma Surgeen2026-06-29T12:26:57.000ZFaire du calme un allié du soin : c'est l'ambition du projet « Réa silencieuse »https://www.pharmaradar360.com/article/vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-predic-f3935a82e2f52d58Pharma Surgeen2026-06-29T12:26:01.000ZVivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meetinghttps://www.pharmaradar360.com/article/eli-lilly-lly-stock-hits-record-high-after-european-drug-approval-and-medicare-e-01f3f0d4caf51aa5Pharma Surgeen2026-06-29T12:25:14.000ZEli Lilly (LLY) Stock Hits Record High After European Drug Approval and Medicare Expansionhttps://www.pharmaradar360.com/article/thailand-and-u-s-strengthen-cooperation-on-produce-pesticide-testing-9561a7e4089ad6b6Pharma Surgeen2026-06-29T12:19:45.000ZThailand and U.S. strengthen cooperation on produce pesticide testinghttps://www.pharmaradar360.com/article/zhejiang-huahai-pharmaceutical-to-sell-off-financial-assets-fb397a039bc99f7ePharma Surgeen2026-06-29T12:18:51.000ZZhejiang Huahai Pharmaceutical to Sell Off Financial Assetshttps://www.pharmaradar360.com/article/edinburgh-hosts-hespal-annual-gathering-d25de79853ff519cPharma Surgeen2026-06-29T12:09:02.000ZEdinburgh hosts HESPAL Annual Gatheringhttps://www.pharmaradar360.com/article/hep-ted-achievements-take-centre-stage-at-international-conference-on-re-shaping-a77ca0f015713756Pharma Surgeen2026-06-29T12:06:31.000ZHEP-TED achievements take centre stage at International Conference on Re-shaping Education for Sustainable Developmenthttps://www.pharmaradar360.com/article/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-i-eaaac117d2919cd7Pharma Surgeen2026-06-29T12:05:20.000Z4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMDhttps://www.pharmaradar360.com/article/prof-dr-moritz-hennemann-has-been-elected-the-new-federal-commissioner-for-data-92a3a90a5f9b8a89Pharma Surgeen2026-06-29T12:05:07.000ZProf. Dr Moritz Hennemann has been elected the new Federal Commissioner for Data Protection and Freedom of Informationhttps://www.pharmaradar360.com/article/tulipe-en-2025-16-de-produits-de-sante-expedies-pour-renforcer-l-acces-aux-soins-9cfb3754765ec187Pharma Surgeen2026-06-29T12:01:07.000ZTulipe en 2025 : +16 % de produits de santé expédiés pour renforcer l’accès aux soinshttps://www.pharmaradar360.com/article/abiomed-introducer-kits-with-impella-heart-pumps-95f39f1bc0f22828Pharma Surgeen2026-06-29T12:00:00.000ZAbiomed Introducer Kits with Impella Heart Pumpshttps://www.pharmaradar360.com/article/4dmt-finishes-phase-3-enrollment-for-wet-amd-gene-therapy-trial-8c97d47379696fedPharma Surgeen2026-06-29T12:00:00.000Z4DMT finishes Phase 3 enrollment for wet AMD gene therapy trialhttps://www.pharmaradar360.com/article/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-i-02784c3ce029e814Pharma Surgeen2026-06-29T12:00:00.000Z4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMDhttps://www.pharmaradar360.com/article/uk-based-scancell-bids-to-buy-nasdaq-listed-neuphoria-to-increase-profile-with-u-232806e792852793Pharma Surgeen2026-06-29T11:55:38.000ZUK-based Scancell bids to buy Nasdaq-listed Neuphoria to ‘increase profile’ with US investors